GlassScriptPhysician profile
Tulin Koparan
NPI 1710045703
$7,136.76
in general payments reported to CMS, 2019-2025
19 companies · $514 in 2025
The $514 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $134 · 2021: $540 · 2022: $1,119 · 2023: $1,570 · 2024: $2,464 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,547.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,276.99 | 2021-2025 | |
| Lumenis Be INC | $1,381.15 | 2024 | M22 |
| Janssen Pharmaceuticals, INC | $903.31 | 2019-2022 | |
| Corium, LLC | $278.98 | 2022-2023 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $240.66 | 2019-2025 | Breztri |
| Pfizer INC. | $166.47 | 2023-2024 | |
| Allergan, INC. | $159.92 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Esperion Therapeutics, INC. | $124.62 | 2021 | |
| Genzyme Corporation | $120.98 | 2019 | |
| Novo Nordisk INC | $120.15 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $54.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.94 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $36.57 | 2019 | |
| Exact Sciences Corporation | $25.00 | 2023 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.99 | 2019 | |
| Glaxosmithkline, LLC. | $20.39 | 2024 | Trelegy Ellipta |
| Galderma Laboratories, L.P. | $15.81 | 2022 | |
| Eisai INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulin Koparan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.